hMG
Menotropins
hMG is not one short peptide but a gonadotropin preparation with FSH and LH activity.
Approvals
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Complex mixture
This is a multi-component mixture, not one chemically defined peptide.
hMG/menotropins are a complex gonadotropin mixture with FSH and LH activity, not one defined short peptide. The approval applies to MENOPUR.
Research areas
Evidence matrix
- Molecular identity
- Complex mixture
hMG/menotropins are a complex gonadotropin mixture with FSH and LH activity, not one defined short peptide. The approval applies to MENOPUR.
- Human research
- Strong
- Replication
- No independent replication
- Clinical endpoints
- Hard patient-relevant outcomes
- Safety
- Characterized by prescribing information or extensive studies
- Approval
- US · Approved
The dimensions are presented separately and are not combined into an overall score.
What the source shows
MENOPUR is used for controlled ovarian stimulation in assisted reproduction.
- MENOPUR: US prescribing informationPrescribing information2018
U.S. National Library of Medicine (DailyMed)
Accessed:
Research gaps
- ·Product identity and activity units matter; a mass in mg alone does not define the preparation.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
These hormonal activities support follicular development.
- MENOPUR: US prescribing informationPrescribing information2018
U.S. National Library of Medicine (DailyMed)
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Reported adverse effects
- ·Key risks include ovarian hyperstimulation, multiple pregnancy and thromboembolic complications.
Contraindications and warnings
- ·MENOPUR is contraindicated, among other settings, in pregnancy, primary ovarian failure, uncontrolled non-gonadal endocrinopathies, hormone-dependent tumors and hypersensitivity.
Interactions
- ·No human drug-interaction studies have been conducted for MENOPUR.
Research gaps
- ·Product identity and activity units matter; a mass in mg alone does not define the preparation.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- MENOPUR: US prescribing informationPrescribing information2018
U.S. National Library of Medicine (DailyMed)
Accessed:
Sources
Sources checked: · Version 2
- MENOPUR: US prescribing informationPrescribing information2018
U.S. National Library of Medicine (DailyMed)
Accessed: